Trial Profile
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Therapeutic Use
- 25 Jan 2022 Status changed from active, no longer recruiting to completed.
- 08 Mar 2019 Status changed from suspended to active, no longer recruiting.
- 22 Aug 2017 Status changed from recruiting to suspended.